CA3022545A1 - Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer - Google Patents
Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer Download PDFInfo
- Publication number
- CA3022545A1 CA3022545A1 CA3022545A CA3022545A CA3022545A1 CA 3022545 A1 CA3022545 A1 CA 3022545A1 CA 3022545 A CA3022545 A CA 3022545A CA 3022545 A CA3022545 A CA 3022545A CA 3022545 A1 CA3022545 A1 CA 3022545A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- snv
- nucleic acids
- specific
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662330043P | 2016-04-29 | 2016-04-29 | |
| US62/330,043 | 2016-04-29 | ||
| PCT/US2017/030291 WO2017190104A1 (en) | 2016-04-29 | 2017-04-29 | Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3022545A1 true CA3022545A1 (en) | 2017-11-02 |
Family
ID=58709564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3022545A Pending CA3022545A1 (en) | 2016-04-29 | 2017-04-29 | Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200181681A1 (enExample) |
| EP (1) | EP3449014A1 (enExample) |
| JP (2) | JP2019518437A (enExample) |
| CN (1) | CN109715826A (enExample) |
| AU (1) | AU2017258799A1 (enExample) |
| BR (1) | BR112018072195A2 (enExample) |
| CA (1) | CA3022545A1 (enExample) |
| EA (1) | EA201892491A1 (enExample) |
| IL (1) | IL262640A (enExample) |
| MX (1) | MX2018013223A (enExample) |
| WO (1) | WO2017190104A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11322224B2 (en) | 2010-05-18 | 2022-05-03 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US11939634B2 (en) | 2010-05-18 | 2024-03-26 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12221653B2 (en) | 2010-05-18 | 2025-02-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US9677118B2 (en) | 2014-04-21 | 2017-06-13 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US12152275B2 (en) | 2010-05-18 | 2024-11-26 | Natera, Inc. | Methods for non-invasive prenatal ploidy calling |
| US20190010543A1 (en) | 2010-05-18 | 2019-01-10 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| US10316362B2 (en) | 2010-05-18 | 2019-06-11 | Natera, Inc. | Methods for simultaneous amplification of target loci |
| BR112013020220B1 (pt) | 2011-02-09 | 2020-03-17 | Natera, Inc. | Método para determinar o estado de ploidia de um cromossomo em um feto em gestação |
| US20140100126A1 (en) | 2012-08-17 | 2014-04-10 | Natera, Inc. | Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data |
| US20180173846A1 (en) | 2014-06-05 | 2018-06-21 | Natera, Inc. | Systems and Methods for Detection of Aneuploidy |
| US11479812B2 (en) | 2015-05-11 | 2022-10-25 | Natera, Inc. | Methods and compositions for determining ploidy |
| RU2760913C2 (ru) | 2016-04-15 | 2021-12-01 | Натера, Инк. | Способы выявления рака легкого |
| GB201618485D0 (en) | 2016-11-02 | 2016-12-14 | Ucl Business Plc | Method of detecting tumour recurrence |
| CA3042722A1 (en) * | 2016-11-02 | 2018-05-11 | The Medical College Of Wisconsin, Inc. | Methods for assessing risk using mismatch amplification and statistical methods |
| CA3067637A1 (en) | 2017-06-20 | 2018-12-27 | The Medical College Of Wisconsin, Inc. | Assessing transplant complication risk with total cell-free dna |
| US12084720B2 (en) | 2017-12-14 | 2024-09-10 | Natera, Inc. | Assessing graft suitability for transplantation |
| US12024738B2 (en) | 2018-04-14 | 2024-07-02 | Natera, Inc. | Methods for cancer detection and monitoring |
| US12234509B2 (en) | 2018-07-03 | 2025-02-25 | Natera, Inc. | Methods for detection of donor-derived cell-free DNA |
| US11931674B2 (en) | 2019-04-04 | 2024-03-19 | Natera, Inc. | Materials and methods for processing blood samples |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
| DE69832158T2 (de) | 1997-02-25 | 2006-08-10 | Arizona Board Of Regents, Tempe | Isolierung und strukturelle aufklärung der kryostatischen linearen und cyclo-depsipeptide dolastatin 16, dolastatin 17, und dolastatin 18 |
| US20030148301A1 (en) * | 1999-12-10 | 2003-08-07 | Toshiya Aono | Method of detecting nucleotide polymorphism |
| JP4116856B2 (ja) * | 2002-10-02 | 2008-07-09 | 富士フイルム株式会社 | １塩基多型の検出方法 |
| US20130071844A1 (en) * | 2010-03-24 | 2013-03-21 | Toppan Printing Co., Ltd. | Method for detecting target base sequence using competitive primer |
| US10077474B2 (en) * | 2012-05-29 | 2018-09-18 | Abbott Molecular, Inc. | Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits |
| US20140242582A1 (en) | 2013-02-28 | 2014-08-28 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities using ligation-based detection and digital pcr |
| DK3194612T3 (da) * | 2014-08-22 | 2024-10-14 | Resolution Bioscience Inc | Fremgangsmåder til kvantitativ genetisk analyse af cellefrit dna |
| HK1252152A1 (zh) * | 2015-04-30 | 2019-05-17 | Medical College Of Wisconsin, Inc. | 用於評估無細胞dna的多重優化錯配擴增(moma)實時pcr |
-
2017
- 2017-04-29 AU AU2017258799A patent/AU2017258799A1/en not_active Abandoned
- 2017-04-29 MX MX2018013223A patent/MX2018013223A/es unknown
- 2017-04-29 EP EP17723819.3A patent/EP3449014A1/en not_active Withdrawn
- 2017-04-29 CA CA3022545A patent/CA3022545A1/en active Pending
- 2017-04-29 EA EA201892491A patent/EA201892491A1/ru unknown
- 2017-04-29 WO PCT/US2017/030291 patent/WO2017190104A1/en not_active Ceased
- 2017-04-29 JP JP2018556974A patent/JP2019518437A/ja active Pending
- 2017-04-29 US US16/097,404 patent/US20200181681A1/en not_active Abandoned
- 2017-04-29 CN CN201780039835.XA patent/CN109715826A/zh active Pending
- 2017-04-29 BR BR112018072195-6A patent/BR112018072195A2/pt not_active IP Right Cessation
-
2018
- 2018-10-28 IL IL262640A patent/IL262640A/en unknown
-
2022
- 2022-02-28 JP JP2022029376A patent/JP2022084647A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017258799A1 (en) | 2018-12-20 |
| US20200181681A1 (en) | 2020-06-11 |
| EP3449014A1 (en) | 2019-03-06 |
| BR112018072195A2 (pt) | 2019-02-12 |
| WO2017190104A1 (en) | 2017-11-02 |
| JP2022084647A (ja) | 2022-06-07 |
| MX2018013223A (es) | 2019-04-22 |
| EA201892491A1 (ru) | 2019-06-28 |
| IL262640A (en) | 2018-12-31 |
| CN109715826A (zh) | 2019-05-03 |
| JP2019518437A (ja) | 2019-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200181681A1 (en) | Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing cancer | |
| US20210301320A1 (en) | Multiplexed optimized mismatch amplification (moma)-cancer risk assessment with non-cancer associated targets | |
| Mastoraki et al. | ESR1 methylation: a liquid biopsy–based epigenetic assay for the follow-up of patients with metastatic breast cancer receiving endocrine treatment | |
| Takai et al. | Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer | |
| US11279979B2 (en) | Method of determining PIK3CA mutational status in a sample | |
| Takai et al. | Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer | |
| Hoshi et al. | Rapid detection of epidermal growth factor receptor mutations in lung cancer by the SMart-Amplification Process | |
| US20190153525A1 (en) | Multiplexed optimized mismatch amplification (moma)-real time pcr for assessing fetal well being | |
| KR102278401B1 (ko) | 빈발 돌연변이의 신속도 및 민감도 검출 방법 | |
| Stadler et al. | SNPase-ARMS qPCR: ultrasensitive mutation-based detection of cell-free tumor DNA in melanoma patients | |
| US20240279745A1 (en) | Systems and methods for multi-analyte detection of cancer | |
| Ball et al. | Circulating tumor DNA as a marker of therapeutic response in patients with renal cell carcinoma: a pilot study | |
| US20220356533A1 (en) | Biomarker composition for diagnosing or predicting prognosis of thyroid cancer, comprising preparation capable of detecting mutation in plekhs1 gene, and use thereof | |
| WO2022157764A1 (en) | Non-invasive cancer detection based on dna methylation changes | |
| KR102416074B1 (ko) | 생물학적 시료의 핵산 품질을 결정하는 방법 | |
| Xiang et al. | Ultra-sensitive and multiplex digital-PCR for quantifying the mutants in cell free DNA by employing invasive reaction as identifier | |
| Atli et al. | Pros and cons for fluorescent in situ hybridization, karyotyping and next generation sequencing for diagnosis and follow-up of multiple myeloma | |
| Chang et al. | Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay | |
| Saldivar et al. | Analytic validation of NeXT Dx™, a comprehensive genomic profiling assay | |
| US12391985B2 (en) | Method of determining PIK3CA mutational status in a sample | |
| EP4486911A1 (en) | Methods for analyzing cytosine methylation and hydroxymethylation | |
| Hanbazazh et al. | Utility of single-gene testing in cancer specimens | |
| Mehta et al. | Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals | |
| EP4624573A1 (en) | Probe/primer library for cancer diagnosis | |
| Prieto-Remon et al. | Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220429 |
|
| EEER | Examination request |
Effective date: 20220429 |
|
| EEER | Examination request |
Effective date: 20220429 |
|
| EEER | Examination request |
Effective date: 20220429 |